A carregar...
OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation
BACKGROUND AND PURPOSE: Larotrectinib is a FDA‐approved oral small‐molecule inhibitor for treatment of neurotrophic tropomyosin receptor kinase fusion‐positive cancer. We here investigated the functions of the multidrug efflux transporters ABCB1 and ABCG2, the SLCO1A/1B (OATP1A/1B) uptake transporte...
Na minha lista:
| Publicado no: | Br J Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7279963/ https://ncbi.nlm.nih.gov/pubmed/32087611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.15034 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|